Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00266409 · ClinicalTrials.gov registry record · Phase 4

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

A Phase 4 study of Generalized Anxiety Disorder and Panic Disorder, sponsored by UCB Pharma.

Completed
Registry status
Phase 4
Development phase
418
Enrollment target
1
Study location

NCT00266409 is a Phase 4 study of Generalized Anxiety Disorder and Panic Disorder that has completed, run by UCB Pharma. The registered enrollment target is 418 participants, above the 206-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (103% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00266409, a Phase 4 study of Generalized Anxiety Disorder and Panic Disorder, has completed, sponsored by UCB Pharma.

COMPLETED
Registry status
Phase 4
Development phase
418 participants
Enrollment target
1
Study location

Study Summary

An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective Serotonin Reuptake Inhibitor (SSRI)or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) to that in subjects treated with a newly prescribed SSRI/SNRI alone. Subjects must be at least 18 years of age and positive for Generalized Anxiety Disorder (GAD)or Panic Disorder. Subjects will be randomized to receive concomitant Niravam™ and an SSRI/SNRI or an SSRI/SNRI alone during the study. Most symptom evaluations will be done using an automated phone interview system. There are 4 clinic visits.

Conditions Studied

Generalized Anxiety Disorder Panic Disorder

Interventions

  • DRUG Niravam
  • DRUG SSRI/SNRI

Study Locations (1)

Wisconsin

  • Schwarz - Milwaukee

Trial Details

FieldValue
Enrollment Target 418 participants
Start Date 2005-10
Est. Completion 2006-06
Phase Phase 4

Sponsor

UCB Pharma

100 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00266409

The ClinicalTrials.gov registry entry for NCT00266409 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 206-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (103% higher). The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Niravam is the first listed.

NCT00266409 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT00266409 about?

NCT00266409 is a clinical study titled "Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder". An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective Serotonin Reuptake Inhibitor (SSRI)or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) to that in subjects treated with...

What is the current status of trial NCT00266409?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 418 participants. The study started on 2005-10. Estimated completion is 2006-06.

What conditions does trial NCT00266409 study?

This clinical trial studies the following conditions: Generalized Anxiety Disorder, Panic Disorder.

What interventions are being tested in trial NCT00266409?

The interventions under investigation include: Niravam (DRUG), SSRI/SNRI (DRUG).

Who is sponsoring clinical trial NCT00266409?

This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00266409 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Generalized Anxiety Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Generalized Anxiety Disorder

All registered trials for this condition

Panic Disorder

All registered trials for this condition

Wisconsin

All trials with a study site in Wisconsin

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.